Search research articles
Contact Us
Filters
Showing results (541-550 of 549) with videos related to
Page
of 55
Sort By:
You have reached the last page of results.
This site can display upto 549 results.
Journal of Neurology
|
July 31, 2022
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update
Thomas H Brannagan, Teresa Coelho, Annabel K Wang, et al.
Neurology and Therapy
|
February 27, 2021
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L<sub>Rx</sub> (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Teresa Coelho, Yukio Ando, Merrill D Benson, et al.
Pain
|
June 8, 2013
Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus
Miroslav Misha Backonja, Nadine Attal, Ralf Baron, et al.
JAMA
|
December 26, 2013
Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial
John L Berk, Ole B Suhr, Laura Obici, et al.
Nature Genetics
|
May 3, 2011
Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss
Christopher J Klein, Maria-Victoria Botuyan, Yanhong Wu, et al.
Brain : a Journal of Neurology
|
February 14, 2015
Defects of mutant DNMT1 are linked to a spectrum of neurological disorders
Jonathan Baets, Xiaohui Duan, Yanhong Wu, et al.
The New England Journal of Medicine
|
July 5, 2018
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Merrill D Benson, Márcia Waddington-Cruz, John L Berk, et al.
The New England Journal of Medicine
|
July 5, 2018
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David Adams, Alejandra Gonzalez-Duarte, William D O'Riordan, et al.
Muscle & Nerve
|
January 8, 2017
Assessing mNIS+7<sub>Ionis</sub> and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial
Peter J Dyck, John C Kincaid, P James B Dyck, et al.
Page
of 55
Search research articles
Search
Showing results (541-550 of 549) with videos related to
Sort By:
Page
of 55
You have reached the last page of results.
This site can display upto 549 results.
Journal of Neurology
|
July 31, 2022
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update
Thomas H Brannagan, Teresa Coelho, Annabel K Wang, et al.
Neurology and Therapy
|
February 27, 2021
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L<sub>Rx</sub> (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Teresa Coelho, Yukio Ando, Merrill D Benson, et al.
Pain
|
June 8, 2013
Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus
Miroslav Misha Backonja, Nadine Attal, Ralf Baron, et al.
JAMA
|
December 26, 2013
Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial
John L Berk, Ole B Suhr, Laura Obici, et al.
Nature Genetics
|
May 3, 2011
Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss
Christopher J Klein, Maria-Victoria Botuyan, Yanhong Wu, et al.
Brain : a Journal of Neurology
|
February 14, 2015
Defects of mutant DNMT1 are linked to a spectrum of neurological disorders
Jonathan Baets, Xiaohui Duan, Yanhong Wu, et al.
The New England Journal of Medicine
|
July 5, 2018
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Merrill D Benson, Márcia Waddington-Cruz, John L Berk, et al.
The New England Journal of Medicine
|
July 5, 2018
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David Adams, Alejandra Gonzalez-Duarte, William D O'Riordan, et al.
Muscle & Nerve
|
January 8, 2017
Assessing mNIS+7<sub>Ionis</sub> and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial
Peter J Dyck, John C Kincaid, P James B Dyck, et al.
Page
of 55